Pulnovo Medical Raises $100M Led by Medtronic

Pulnovo Medical has successfully closed an oversubscribed $100 million financing round, signaling a significant leap forward in its mission to develop novel treatments for pulmonary hypertension and heart failure. The substantial capital infusion was spearheaded by a strategic investment from Medtronic, a global leader in medical technology, underscoring strong market confidence in Pulnovo's innovative Pulmonary Artery Denervation (PADN) System.

This funding round saw continued backing from prominent existing investors including EQT, Qiming Venture Partners, Gaorong Ventures, OrbiMed, and LAV. The company also welcomed new strategic partners, notably HSG (formerly Sequoia China), alongside other significant international financial institutions. The oversubscribed nature of the round highlights the compelling clinical progress and future potential of Pulnovo's technology in addressing critical unmet needs within the cardiopulmonary disease space.

Beyond the financing, Pulnovo Medical and Medtronic have established a commercial agreement. This collaboration is designed to harness Medtronic's extensive global commercialization infrastructure, potentially paving the way for broader market access and patient reach for Pulnovo's therapies. This strategic alliance is a key component of Pulnovo's plan to transition from a product-focused entity to a fully integrated global platform.

The PADN System, Pulnovo's flagship technology, targets an overactive sympathetic nerve activity implicated in the progression of cardiopulmonary diseases. To date, approximately 1,500 PADN procedures have been performed worldwide, with regulatory approvals secured in seven countries. The company is actively expanding its commercial presence across the European Union, the Middle East, and China. In the United States, the PADN System has received FDA Breakthrough Device designation, and two Investigational Device Exemption (IDE) trials are underway, led by renowned cardiologist Dr. Gregg Stone of Mount Sinai.

Proceeds from this financing will fuel crucial initiatives, including the advancement of ongoing clinical development programs, the execution of global regulatory strategies, the expansion of international commercial operations, and continued investment in the company's core technology. The appointment of Andre Xiao as Chief Strategy Officer, with prior experience at firms like Citadel and Millennium Management, further bolsters Pulnovo's capacity to navigate global capital markets and strategic partnerships.

The market for advanced cardiovascular and pulmonary therapies is experiencing robust growth, driven by an aging global population and increasing prevalence of chronic conditions. Innovations like Pulnovo's PADN system, which offer minimally invasive solutions targeting underlying disease mechanisms, are well-positioned to capture significant market share. The inclusion of PADN in international clinical guidelines, such as the 2022 ESC/ERS Guidelines for pulmonary hypertension, further validates its therapeutic value and potential for widespread adoption.